- Home
- CCIA vs SRPT Comparison
CCIA vs SRPT Comparison
Compare CCIA & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- SRPT
- Stock Information
- Founded
- CCIA N/A
- SRPT 1980
- Country
- CCIA
- SRPT United States
- Employees
- CCIA N/A
- SRPT N/A
- Industry
- CCIA
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- SRPT Health Care
- Exchange
- CCIA Nasdaq
- SRPT Nasdaq
- Market Cap
- CCIA N/A
- SRPT N/A
- IPO Year
- CCIA 2023
- SRPT 1997
- Fundamental
- Price
- CCIA $25.49
- SRPT $20.28
- Analyst Decision
- CCIA
- SRPT Buy
- Analyst Count
- CCIA 0
- SRPT 26
- Target Price
- CCIA N/A
- SRPT $70.92
- AVG Volume (30 Days)
- CCIA N/A
- SRPT 6.5M
- Earning Date
- CCIA N/A
- SRPT 08-06-2025
- Dividend Yield
- CCIA N/A
- SRPT N/A
- EPS Growth
- CCIA N/A
- SRPT N/A
- EPS
- CCIA N/A
- SRPT N/A
- Revenue
- CCIA N/A
- SRPT $2,233,371,000.00
- Revenue This Year
- CCIA N/A
- SRPT $26.87
- Revenue Next Year
- CCIA N/A
- SRPT $3.15
- P/E Ratio
- CCIA N/A
- SRPT N/A
- Revenue Growth
- CCIA N/A
- SRPT 59.15
- 52 Week Low
- CCIA N/A
- SRPT $18.30
- 52 Week High
- CCIA N/A
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- CCIA 46.36
- SRPT 20.82
- Support Level
- CCIA $25.47
- SRPT $18.30
- Resistance Level
- CCIA $25.69
- SRPT $22.98
- Average True Range (ATR)
- CCIA 0.09
- SRPT 2.20
- MACD
- CCIA -0.00
- SRPT -1.46
- Stochastic Oscillator
- CCIA 31.12
- SRPT 8.90
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.